Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.36 |
| ▸ | CFTR | P13569 | 3/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16179402 | 0.93 | PDE4B (0.38) | KEAP1NFE2L2PDE10ACFTRCYP11B2 | |
| SCHEMBL17477019 | 0.91 | PDE10A (0.35) | KEAP1NFE2L2PDE10ACFTR | |
| SCHEMBL17477018 | 0.88 | RAB9A (0.39) | PDE10AHDAC1 | |
| SCHEMBL17477024 | 0.87 | KEAP1 (0.37) | KEAP1NFE2L2PDE10ACFTRCYP11B2 | |
| SCHEMBL17476985 | 0.86 | GRIN2B (0.35) | — | |
| SCHEMBL17476961 | 0.85 | CFTR (0.33) | CFTR | |
| SCHEMBL17476894 | 0.83 | S1PR1 (0.36) | — | |
| SCHEMBL17477026 | 0.83 | PDE4B (0.44) | — | |
| SCHEMBL17477017 | 0.83 | PDE4B (0.39) | KEAP1NFE2L2PDE10A | |
| SCHEMBL17476950 | 0.82 | GPR84 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986600-B1 | SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2017-07-05 | — | — | EP | disclosed |
| US-9527832-B2 | Substituted condensed pyrimidine compounds | Grünenthal GmbH (DE) | 2016-12-27 | — | — | US | disclosed |
| US-20160031857-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031857-A1 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS | TYMP, PDE4A, DPYD | KEAP1 1772/4885NFE2L2 1067/4885PDE10A 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.